TRexBio Q3 2026 Financial Results and Pipeline Updates
Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
TRexBio Reports Third Quarter 2026 Financial Results and Recent Business Highlights
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2026 -- TRexBio, Inc. (Nasdaq: TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines, today reported its financial results for the third quarter ended September 30, 2026, alongside recent business highlights.
The company highlighted positive Phase 1a results for its lead product candidate TRB-061, supporting proof of mechanism, with topline Phase 1b data in atopic dermatitis anticipated in mid-2027. Additionally, TRexBio completed a $133.5 million initial public offering in October 2026, extending its expected cash runway into the second half of 2029.
- Reported positive Phase 1a topline results for TRB-061, demonstrating reproducible activation and expansion of immunoregulatory Tregs in healthy volunteers.
- TRB-071 is advancing through IND-enabling studies, with a Phase 1 clinical trial expected to initiate in the first half of 2027.
- Eli Lilly intends to advance partnered program TRB-051 into a Phase 2a clinical trial in lupus with cutaneous involvement.
Key Highlights
- Cash, cash equivalents, and marketable securities totaled $78.2 million as of September 30, 2026, excluding approximately $119.0 million in net proceeds from the October 2026 IPO.
- Research and development (R&D) expenses were $11.4 million for the third quarter of 2026, compared to $7.0 million for the same period in 2025.
- General and administrative (G&A) expenses were $2.5 million for the third quarter of 2026, compared to $1.7 million for the third quarter of 2025.
- Net loss was $13.2 million for the third quarter of 2026, compared to $7.9 million for the third quarter of 2025.
Financial Highlights
